CLAIM CARD
Mechanistically, colchicine's well-characterized anti-inflammatory actions — including inhibition of the NLRP3 inflammasome, tubulin polymerization disruption, and neutrophil chemotaxis suppression — provide a plausible basis for inflammaging modulation. However, the corpus contains no direct human mechanistic RCT data for colchicine on inflammaging biomarkers. Li 2025b's cocoa extract trial, which targets overlapping inflammatory pathways via flavanol-mediated reductions in hsCRP, offers indirect support that sustained anti-inflammatory intervention can alter inflammaging markers over a 2-year period. The absence of comparable colchicine-specific RCT data in this corpus means that mechanistic plausibility remains unconfirmed by human experimental evidence.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022